entertainment -WSS

entertainment

author：comprehensive 2025-08-10 11:42:27 - browse：29

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

WSS

Stop Congress from blocking public access to science

Will an HIV vaccine ever be a reality?

What we owe ALS patients — and why one company fell short

RSV injection headlines need to be accurate for good uptake

European officials brace for rough respiratory virus season

New oral drug delivery patch is modeled after octopus tentacles

focus

entertainment

entertainment

Sports medicine is finally prioritizing gender equality

New oral drug delivery patch is modeled after octopus tentacles

United colonoscopy coverage change 'may cost lives,' doctors say

RSV injection headlines need to be accurate for good uptake

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Congress must protect the remaining independent doctors

Duchenne breakthrough therapy leaves behind pioneering families

What we owe ALS patients — and why one company fell short

Walensky prepares to leave CDC — and Congress — behind

CDC picks Alphabet's Verily for wasterwater surveillance contract

focus

Having children helps parents live longer, especially after age 80

Latigo launches with $135 million for Vertex

Why Eli Lilly’s earnings didn’t quite live up to the hype

With Roe v Wade overturned, abortion providers work to adapt

European officials brace for rough respiratory virus season

AMAs digital advisors table RPM coding reform proposal, again

leisure time

entertainment

hotspot

Wikipedia